AbbVie sees near-term slowdown; looks prepared to tackle patent expiration
AbbVie, Inc. (NYSE: ABBV) has delivered yet another quarter of strong top-line and earnings performance but issued cautious guidance for fiscal 2023 citing an estimated drop in sales due to […]
The post AbbVie sees near-term slowdown; looks prepared to tackle patent expiration first appeared on AlphaStreet.